Albumedix announced that its albumin-based VELTIS® half-life extension technology is being used by CSL Behring in IDELVION®, a therapy recently authorized for the treatment of haemophilia B in the U.S. The application of Albumedix’s VELTIS technology in the drug delivers an extended half-life which will improve the lives of patients living with the condition by reducing the frequency of injections up to once every 14 days. The U.S. Centers for Disease Control and Prevention, report that the condition affects approximately one in 25,000 male births.
VELTIS technology is a platform of native and engineered human albumins. When combined with a drug candidate it offers the potential for adaptive control of therapeutic half-life.
The platform has the potential to significantly improve the treatment options available to haemophilia patients by maintaining the activity levels of therapeutics for prolonged periods and opening the door towards extended dosing intervals.
